Carlos Mesia

L'hospitalet De Llobregat, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM).

Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM).

Journal: Journal of neuro-oncology

Published: March 13, 2024

Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma.

Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma.

Journal: Journal of neuro-oncology

Published: January 30, 2024

A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma.

A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma.

Journal: Journal of neuro-oncology

Published: October 11, 2023

Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker.

Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker.

Journal: Cells

Published: January 22, 2023

In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma.

In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma.

Journal: Scientific reports

Published: June 01, 2022

Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy.

Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 16, 2020

A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01).

A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01).

Journal: Neuro-oncology

Published: April 25, 2020

Contrast-enhancement in supratentorial low-grade gliomas: a classic prognostic factor in the molecular age.

Contrast-enhancement in supratentorial low-grade gliomas: a classic prognostic factor in the molecular age.

Journal: Journal of neuro-oncology

Published: March 16, 2019

Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients.

Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: February 05, 2018

Pseudoprogression as an adverse event of glioblastoma therapy.

Pseudoprogression as an adverse event of glioblastoma therapy.

Journal: Cancer medicine

Published: July 25, 2017

Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study.

Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study.

Journal: Breast cancer research and treatment

Published: March 03, 2015

Bevacizumab for the treatment of glioblastoma.

Bevacizumab for the treatment of glioblastoma.

Journal: Clinical Medicine Insights. Oncology

Published: July 12, 2013

Showing 1-12 of 14

Last Updated: 09/26/2026